International journal of clinical practice
-
Int. J. Clin. Pract. · Sep 2020
Cardiovascular outcomes, heart failure and mortality in Type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): a systematic review and meta-analysis of observational cohort studies.
Cardiovascular outcomes trials (CVOTs) have assessed the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on major adverse cardiovascular events (MACE) and mortality in high cardiovascular (CV) risk populations. Observational research can provide complementary evidence about these effects in unselected populations. ⋯ Pooled results of EHDs' studies assessing GLP-1 RAs effects favoured GLP-1 RAs for all-cause mortality and MACE while were neutral for HHF. Results should be interpreted cautiously because of studies' substantial heterogeneity and limitations of observational research.